CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Imidazole antifungal
Updated · Methodology
Mechanism
Miconazole inhibits the liver enzyme CYP3A4, and the miconazole oral gel summary of product characteristics (SmPC) calls it a clinically potent inhibitor of this enzyme (miconazole oral gel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPC contraindicates oral miconazole with ergot alkaloids and names dihydroergotamine among them, because their higher blood levels can cause ergotism, that is, ergot alkaloid poisoning (AEMPS). According to the US dihydroergotamine labels, CYP3A4 inhibition raises dihydroergotamine blood levels and increases the risk of vasospasm leading to cerebral or limb ischaemia (dihydroergotamine labels, US Food and Drug Administration, FDA). With itraconazole, the peak level and the area under the curve (AUC) of dihydroergotamine itself rose by 14% and 19%. For its main metabolite, an equally potent venoconstrictor in experimental models, they rose about 4-fold and 3-fold (dihydroergotamine FDA label). Patients hold the gel in the mouth and then swallow it. A 60 mg dose of the gel gives peak plasma miconazole levels of 31–49 ng/mL (miconazole oral gel SmPC, AEMPS). Less than 1% of a cream dose is absorbed (miconazole cream SmPC, AEMPS). Each Spanish vaginal ovule contains 100 mg of miconazole with 300 mg of metronidazole. Their SmPC gives data for 1200 mg miconazole ovules: levels more than 100 times lower than after oral or intravenous use (vaginal ovule SmPC, AEMPS).
Symptoms
Vasospasm from dihydroergotamine causes muscle pain, numbness, coldness, pallor and cyanosis of the fingers and toes. In people with poor circulation, persistent vasospasm can lead to gangrene or death. Myocardial and colonic ischaemia have also been reported (dihydroergotamine label, US Food and Drug Administration, FDA). Leg ischaemia presents with cramping and pain in the legs or hips, heaviness or tightness in the leg muscles, burning or aching pain in the feet or toes at rest, numbness, tingling, weakness, and coldness or colour changes in the legs or feet. Cerebral ischaemia presents with slurred speech and sudden weakness (dihydroergotamine FDA label). An excess of dihydroergotamine causes numbness, pain and cyanosis of the limbs with weak or absent pulses, respiratory depression, a rise in blood pressure usually followed by a fall, confusion, delirium, seizures and coma, as well as nausea, vomiting and abdominal pain (dihydroergotamine FDA label).
Management
The combination is contraindicated for oral miconazole. The miconazole oral gel summary of product characteristics (SmPC) names dihydroergotamine among the ergot alkaloids that must not be used with oral miconazole (miconazole oral gel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US dihydroergotamine labels contraindicate it with strong CYP3A4 inhibitors, including antifungals (dihydroergotamine labels, US Food and Drug Administration, FDA). They do not name miconazole, but the gel SmPC itself calls miconazole a clinically potent CYP3A4 inhibitor (miconazole oral gel SmPC, AEMPS). Dihydroergotamine is not on the Spanish medicines register, so there is no Spanish SmPC for it. Patients hold the gel in the mouth and then swallow it, so the contraindication also applies when it is used for oral or oesophageal candidiasis (miconazole oral gel SmPC, AEMPS). The miconazole cream and vaginal ovule SmPCs do not mention ergot alkaloids. According to them, little miconazole reaches the blood and clinically relevant interactions are rare (miconazole cream and vaginal ovule SmPCs, AEMPS). The US label of miconazole buccal tablets, which are not available in Spain, states that absorption is minimal but that an interaction with ergot alkaloids cannot be ruled out (miconazole FDA label). If the two drugs have nevertheless been taken together and signs of vasospasm appear, such as numb, cold, pale or bluish fingers or toes, leg pain and cramps, slurred speech or sudden weakness, stop dihydroergotamine at once and seek emergency care (dihydroergotamine FDA labels). In overdose, stop dihydroergotamine, give supportive care with monitoring of vital signs, and observe the patient for at least 24 hours or while symptoms persist (dihydroergotamine FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: ATZUMI (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid 0982a44a-dc0c-75c0-e063-6394a90a6d6c, revisión 06/2026 (versión 3), secciones 4, 5.5, 5.6 y 7.2
- FDA: TRUDHESA (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid b81397b0-910d-4eb4-8fee-a9a3c9d94d63, revisión 09/2026 (versión 7), secciones 4 y 7.2
- AEMPS: Ficha técnica: Daktarin 20 mg/g gel oral, miconazol (nº registro 55962), sección 4.3 (2026)– AEMPS, CIMA, nº registro 55962 (Daktarin 20 mg/g gel oral, JNTL Consumer Health), revisión 06/2026, secciones 4.3, 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Blasgina óvulos vaginales (nº registro 50441), sección 4.5 (2026)– AEMPS, CIMA, nº registro 50441 (Blasgina óvulos vaginales, Almirall), revisión 09/2026, secciones 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Miconazol crema (nº registro 50271), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 50271 (Daktarin 20 mg/g crema), revisión 06/2026, secciones 4.4, 4.5 y 5.2 (en el HTML de CIMA siguen al apartado 4.3, sin ancla propia)
- FDA: ORAVIG (miconazole) buccal tablets prescribing information (2026)– FDA, DailyMed setid dc2427ff-e566-4b48-b289-9e51c011250a, Galt Pharmaceuticals, revisión 01/2026 (versión 3), secciones 7.1, 7.2 y 12.3